Stock Analysis

What Does Zepp Health Corporation's (NYSE:ZEPP) Share Price Indicate?

NYSE:ZEPP
Source: Shutterstock

Zepp Health Corporation (NYSE:ZEPP), is not the largest company out there, but it received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$6.65 at one point, and dropping to the lows of US$2.45. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Zepp Health's current trading price of US$2.56 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Zepp Health’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

View our latest analysis for Zepp Health

What is Zepp Health worth?

According to my valuation model, Zepp Health seems to be fairly priced at around 6.6% below my intrinsic value, which means if you buy Zepp Health today, you’d be paying a reasonable price for it. And if you believe that the stock is really worth $2.74, then there isn’t much room for the share price grow beyond what it’s currently trading. What's more, Zepp Health’s share price may be more stable over time (relative to the market), as indicated by its low beta.

Can we expect growth from Zepp Health?

earnings-and-revenue-growth
NYSE:ZEPP Earnings and Revenue Growth March 16th 2022

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. In Zepp Health's case, its revenues over the next few years are expected to grow by 41%, indicating a highly optimistic future ahead. If expense does not increase by the same rate, or higher, this top line growth should lead to stronger cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? It seems like the market has already priced in ZEPP’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?

Are you a potential investor? If you’ve been keeping tabs on ZEPP, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

If you want to dive deeper into Zepp Health, you'd also look into what risks it is currently facing. Every company has risks, and we've spotted 3 warning signs for Zepp Health you should know about.

If you are no longer interested in Zepp Health, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Valuation is complex, but we're here to simplify it.

Discover if Zepp Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.